Regen BioPharma Inc (RGBP)

[PressAnyKey-]

Edit“ we aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale.”

https://www.crunchbase.com/organization/bio-matrix-scientific-group

Link https://t.co/eXSgVJxzdw

— jules (@CreativeCapita7) November 19, 2021

The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale.